All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F21%3A73609336" target="_blank" >RIV/61989592:15310/21:73609336 - isvavai.cz</a>

  • Result on the web

    <a href="https://worldwide.espacenet.com/patent/search/family/068384115/publication/EP3601287A1?q=EP3601287" target="_blank" >https://worldwide.espacenet.com/patent/search/family/068384115/publication/EP3601287A1?q=EP3601287</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions

  • Original language description

    The present invention relates to novel 2,6-disubstituted-9-cyclopentyl-9H-purines of general formula I, capable of inhibiting the activity of kinases such as FLT3, CDKs and PDGFRs in cancer and other related proliferative diseases. The invention further includes pharmaceutical compositions containing the 2,6-disubstituted-9-cyclpentyl-9H-purines. Compounds of the present invention can be used as active ingredients of a pharmaceutical compositions for treating acute myeloid leukemia (AML).

  • Czech name

  • Czech description

Classification

  • Type

    P - Patent

  • CEP classification

  • OECD FORD branch

    10608 - Biochemistry and molecular biology

Result continuities

  • Project

    <a href="/en/project/GA19-09086S" target="_blank" >GA19-09086S: Dual FLT3/CDK9 inhibition as a possible therapeutical approach for mixed lineage leukemia</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2021

  • Confidentiality

    C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.

Data specific for result type

  • Patent/design ID

    EP3601287

  • Publisher

    EPO_1 -

  • Publisher name

    European Patent Office

  • Place of publication

    Munich, The Hague, Berlin, Vienna, Brussels

  • Publication country

  • Date of acceptance

    Dec 15, 2021

  • Owner name

    Univerzita Palackého v Olomouci

  • Method of use

    A - Výsledek využívá pouze poskytovatel

  • Usage type

    A - K využití výsledku jiným subjektem je vždy nutné nabytí licence